Working… Menu

Phase II Study of the Trifunctional Antibody Catumaxomab Administered Intra- and Postoperatively in Patients With Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00563836
Recruitment Status : Completed
First Posted : November 26, 2007
Last Update Posted : October 3, 2012
Information provided by (Responsible Party):
Neovii Biotech

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 2008
Actual Study Completion Date : August 2010